Recent research have centered on the overlap of GLP|glucose-dependent insulinotropic polypeptide|glucagon receptor activator therapies and DA communication. While GLP activators are increasingly employed for treating type 2 T2DM, their emerging impacts on reinforcement circuits, specifically gove